Can a Two-Drug combo keep CLL at bay for years? a 10-Year watch begins

This study follows people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who previously received a combination of ibrutinib and venetoclax in the CAPTIVATE trial. Researchers will track their health for up to 10 years to see what treatments they need if the disease returns, how long the initial response lasts, and whether the cancer becomes resistant. Participants may also provide blood samples to check for tiny amounts of remaining cancer cells and genetic changes. The goal is to understand the long-term real-world impact of this treatment combination.